PlainPharmaWatch

CMS Open Payments · Program Year 2024

Next Science LLC

Next Science LLC reported $829,878.35 across General Payments, Research, and Ownership to 1,698 physicians and teaching hospitals across 1,710 transactions.

$829.9K
All-tracks total
1,710
Transactions
1,698
Recipients
+$393.0K
General Payments vs PY2023

Next Science LLC reported $829,878.35 across all CMS Open Payments tracks (General + Research + Ownership) to 1,698 physicians and teaching hospitals in Program Year 2024 - ranking #664 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $546,356.47, averaging $488.74 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer next-science-llc Next Science LLC

$829.9K · #664/1,925 · 0.0% industry · PY2024

  • TOT $829.9K
  • RANK #664
  • SHARE 0.0%
  • TXN 1,710
  • RCP 1,698
  • CAT 2
  • GEN $546.4K
  • ΔGEN +$393.0K
  • TOP1 34.5%
  • PY 2024

Nearest volume peer: Spineart USA Inc ($830.2K)

Genesys Orthopedics Systems,…$837.2KVertos Medical, Inc.$836.6KSpineart USA Inc$830.2KNext Science LLC (this)$829.9KSpine Wave, Inc.$825.7K
All-tracks payment totals near Next Science LLC (CMS Open Payments PY2024)

Next Science LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Next Science LLC's CMS-reported General Payments increased by $393.0K (+256.3%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: NEXT SCIENCE LLCPY2023: NEXT SCIENCE LLCPY2024: Next Science LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$153.3KPY2024$546.4K
PY2023
$153,340.01
PY2024
$546,356.47

What the Data Shows for Next Science LLC

Next Science LLC ranks #664 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $829,878.35 across 1,710 transactions to 1,698 physicians and teaching hospitals - $485.31 per transaction and $488.74 per recipient on average.

Of the 2 general-payment categories charted below, "Consulting Fee" is the largest at $471.4K across 169 transactions, 86.3% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Next Science LLC made 2 types of general payments. "Consulting Fee" is the largest category at $471.4K, 86.3% of General Payments.

How Next Science LLC divides its payments

Ranked by total dollars reported per category

1. Consulting Fee$471.4K2. Food and Beverage$75.0K
Payment Type Amount Transactions
Consulting Fee $471.4K 169
Food and Beverage $75.0K 1,529

Recipient Concentration in General Payments

The five largest recipient relationships account for $468,003.31 (85.7%) of $546,356.47 in this company's General Payments records across 884 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Next Science LLC

The five named recipients with the highest reported General Payments from this company

Patricia Stevenson$188.4KJon Minter$180.3KMatthew Regulski$91.3KAndrew Wickline$6.0KBerdj Stepanian$2.0K
  1. 1

    Patricia Stevenson

    $188,353.68 across 41 reported transactions

  2. 2

    Jon Minter

    $180,341.22 across 17 reported transactions

  3. 3

    Matthew Regulski

    $91,346.32 across 51 reported transactions

  4. 4

    Andrew Wickline

    $6,000.00 across 2 reported transactions

  5. 5

    Berdj Stepanian

    $1,962.09 across 50 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Next Science LLC's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Next Science LLC.

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Next Science LLC.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Next Science LLC's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.